News & events Upcoming events AASLD 2019 - The Liver Meeting® Nov 8, 2019 - Nov 12, 2019 Boston, MA , United States More info and meet us there XXII Congresso Nazionale SIGU Nov 13, 2019 - Nov 16, 2019 Rome , Italy More info and meet us there Annual Meeting of the Royal Belgian Society of Laboratory Medicine (RBSLM) Nov 15, 2019 - Nov 15, 2019 Brussels , Belgium More info and meet us there See all upcoming events Latest news INNO-LiPA® HPV Genotyping Extra II now CE marked for use on self-collected first-void urine samples Sep 16, 2019 Fujirebio Europe announced today that its genotyping assay for Human Papilloma Virus (HPV), INNO-LiPA HPV Genotyping Extra II received a CE... Read more Fujirebio launches the automated Lumipulse® G AMH assay for accurate assessment of ovarian reserve Apr 26, 2019 Fujirebio Europe announces the release of the Lumipulse G AMH assay for automated quantitative measurement of anti-Müllerian hormone in... Read more Fujirebio expands its INNO-LiPA® CFTR assay portfolio with the launch of INNO-LiPA CFTR Extra Mar 18, 2019 Fujirebio Europe announces the release of the new INNO-LiPA® CFTR Extra assay for the detection of 18 new disease-causing cystic fibrosis... Read more Fujirebio Europe announces the availability of the Lumipulse® G pTau 181 and β-Amyloid 1-40 assays extending its offer of fully automated assays as an aid in the early diagnosis of Alzheimer’s disease Nov 27, 2018 Fujirebio Europe today announced the availability of the Lumipulse G pTau 181 and β-Amyloid 1-40 assays for its fully automated LUMIPULSE G... Read more Fujirebio Diagnostics Announces FDA Clearance of Lumipulse G B•R•A•H•M•S PCT Assay Jun 12, 2018 Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has received U.S. Food and Drug Administration (FDA)... Read more Fujirebio Europe announces CE marking of the Lumipulse® G CK-MB assay, used to aid in the diagnosis of Acute Myocardial Infarction (AMI) Oct 13, 2017 Fujirebio Europe today announced the CE marking of the Lumipulse G CK-MB immunoassay, which can be used as an aid in the diagnosis of Acute... Read more Load More
AASLD 2019 - The Liver Meeting® Nov 8, 2019 - Nov 12, 2019 Boston, MA , United States More info and meet us there
Annual Meeting of the Royal Belgian Society of Laboratory Medicine (RBSLM) Nov 15, 2019 - Nov 15, 2019 Brussels , Belgium More info and meet us there
INNO-LiPA® HPV Genotyping Extra II now CE marked for use on self-collected first-void urine samples Sep 16, 2019 Fujirebio Europe announced today that its genotyping assay for Human Papilloma Virus (HPV), INNO-LiPA HPV Genotyping Extra II received a CE... Read more
Fujirebio launches the automated Lumipulse® G AMH assay for accurate assessment of ovarian reserve Apr 26, 2019 Fujirebio Europe announces the release of the Lumipulse G AMH assay for automated quantitative measurement of anti-Müllerian hormone in... Read more
Fujirebio expands its INNO-LiPA® CFTR assay portfolio with the launch of INNO-LiPA CFTR Extra Mar 18, 2019 Fujirebio Europe announces the release of the new INNO-LiPA® CFTR Extra assay for the detection of 18 new disease-causing cystic fibrosis... Read more
Fujirebio Europe announces the availability of the Lumipulse® G pTau 181 and β-Amyloid 1-40 assays extending its offer of fully automated assays as an aid in the early diagnosis of Alzheimer’s disease Nov 27, 2018 Fujirebio Europe today announced the availability of the Lumipulse G pTau 181 and β-Amyloid 1-40 assays for its fully automated LUMIPULSE G... Read more
Fujirebio Diagnostics Announces FDA Clearance of Lumipulse G B•R•A•H•M•S PCT Assay Jun 12, 2018 Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has received U.S. Food and Drug Administration (FDA)... Read more
Fujirebio Europe announces CE marking of the Lumipulse® G CK-MB assay, used to aid in the diagnosis of Acute Myocardial Infarction (AMI) Oct 13, 2017 Fujirebio Europe today announced the CE marking of the Lumipulse G CK-MB immunoassay, which can be used as an aid in the diagnosis of Acute... Read more
